Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia

Guerbet SA

23/04/2026 16:57

Overview

France-based medical imaging firm's Q1 revenue rose 2.6% at CER, but fell 1.5% reported

Revenue growth driven by EMEA and Asia; Americas declined due to Raleigh site issues

Company continues Raleigh remediation and launches redundancy plan in France

Outlook

Guerbet will announce 2026 financial targets by 23 July at the latest

Company expects full normalization of Raleigh site batch release rate by year-end

Guerbet anticipates full effect of transformation plan during 2027 financial yr

Result Drivers

EMEA AND ASIA GROWTH - Revenue growth in EMEA and Asia driven by increased volumes, with France recovering from prior supply reforms and Asian markets led by Japan, South Korea, and Taiwan

AMERICAS DECLINE - Revenue in the Americas fell due to reduced volumes from slower batch releases at the Raleigh site

MRI AND INTERVENTIONAL RADIOLOGY - MRI revenue rose on higher Elucirem sales and new market launches; Interventional Radiology grew on strong Lipiodol volumes

Company press release: ID:nGNEbldSDn

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
EUR 177.40 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Guerbet SA is €12.00, about 20.7% above its April 22 closing price of €9.94

The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)